期刊文献+

头颈部恶性肿瘤的分子靶向治疗进展 被引量:5

原文传递
导出
摘要 头颈部恶性肿瘤(head and neck cancer)是指颅底到锁骨上、颈椎前范围内的所有恶性肿瘤,是全球范围内的第5大常见肿瘤,在欧美国家占全部恶性肿瘤的10.0%以下,在我国约占19.9%-30.2%。手术、放疗的改进对部分类型的早期头颈部肿瘤患者疗效明显提高,但70%~80%的患者在就诊时已是局部晚期或晚期。头颈部恶性肿瘤手术、放疗后,5年内30%~50%死于肿瘤复发,20%~40%死于远处转移;
出处 《中国综合临床》 2010年第5期549-551,共3页 Clinical Medicine of China
  • 相关文献

参考文献16

  • 1Bentzen SM,Atasoy BM,Daley FM,et al.Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial[J].J Clin Oncol,2005,23 (24):5560-5567.
  • 2Eriksen JG,Steiniche T,Askaa J,et al.The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck[J].Int J Radiat Oncol Biol Phys,2004,58(2):561-566.
  • 3Bonner JA,Harari PM,Giralt J,et al.Radiotherapy plus cetuximsb for squamous-cell carcinoma of the head and neck[J].N Engl J Med,2006,354(6):567-578.
  • 4Baselga J,Trigo JM,Bourhis J,et al.Phase Ⅱ multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck[J].J Clin Oncol,2005,23 (24):5568-5577.
  • 5Herbst RS,Arquette M,Shin DM,et al.Phase Ⅱ multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck[J].J Clin Oncol,2005,23(24):5578-5587.
  • 6Chan AT,Hsu MM,Gob BC,et al.Multicenter,phase Ⅱ study of cetuximab in combination with carboplatin in patients with recurrent or metastatic ansopharyngeal carcinoma[J].J Clin Oncol,2005,23(15):3568-3576.
  • 7Crombet T,Osorio M,Cruz T,et al.Use of the humanized antiepidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients[J].J Clin Oncol,2004,22 (9):1646-1654.
  • 8Cohen EE,Kane MA,List MA,et al.Phase Ⅱ trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck[J].Clin Cancer Res,2005,11(23):8418-8424.
  • 9Williams KJ,Teffer BA,Strafford IJ,et al.ZD1839 ('Iressa'),a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor,potentiates radiotherapy in a human colorectal cancer xenograft model[J].Br J Cancer,2002,86 (7):1157-1161.
  • 10Soulieres D,Senzer NN,Vokes EE,et al.Multicenter phase Ⅱ study of erlotinib,an oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with recurrent or metastatic squamous cell cancer of the head and neck[J].J Clin Oncol,2004,22(1):77-85.

二级参考文献39

共引文献146

同被引文献61

引证文献5

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部